Apoptotic adipose-derived mesenchymal stem cell therapy protects against lung and kidney injury in sepsis syndrome caused by cecal ligation puncture in rats

Stem Cell Research and Therapy

Volumn 4, Issue 6, 2013, Pages

  Sung, Pei Hsun ^a   Chang, Chia Lo ^a   Tsai, Tzu Hsien ^a   Chang, Li Teh ^b   Leu, Steve ^a   Chen, Yung Lung ^a   Yang, Chic Chao ^a   Chua, Sarah ^a   Yeh, Kuo Ho ^a   Chai, Han Tan ^a   Chang, Hsueh Wen ^c   Chen, Hong Hwa ^a   Yip, Hon Kan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b MEIHO UNIVERSITY   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD3 ANTIGEN; CREATININE; CYTOCHROME C; GELATINASE B; GLUCOCORTICOID RECEPTOR; GLUTATHIONE PEROXIDASE; HEME OXYGENASE 1; HISTONE H2AX; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE DERIVED STEM CELL; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; INFLAMMATORY CELL; KIDNEY INJURY; LEUKOCYTE COUNT; LUNG INJURY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; SEPSIS; THERAPY EFFECT;

RATTUS;

ADIPOSE TISSUE; ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CECUM; CELL- AND TISSUE-BASED THERAPY; CREATININE; INTESTINAL PERFORATION; KIDNEY; LEUKOCYTE COUNT; LUNG INJURY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MITOCHONDRIA; MODELS, ANIMAL; NF-KAPPA B; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890819666     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt385     Document Type: Article

References (29)

1. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL, International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases, et al. Crit Care Med 2008 36 296 327 10.1097/01.CCM.0000298158.12101.41 18158437
2. Impact of the Surviving Sepsis Campaign on the recognition and management of severe sepsis in the emergency department: are we failing? Cronshaw HL, Daniels R, Bleetman A, Joynes E, Sheils M, Emerg Med J 2011 28 670 675 10.1136/emj.2009.089581 20660901
3. Use of a protocolized approach to the management of sepsis can improve time to first dose of antibiotics. Tipler PS, Pamplin J, Mysliwiec V, Anderson D, Mount CA, J Crit Care 2013 28 148 151 10.1016/j.jcrc.2012.08.021 23102528
4. Prediction of outcome from community-acquired severe sepsis and septic shock in tertiary-care university hospital in a developing country. Grozdanovski K, Milenkovic Z, Demiri I, Spasovska K, Crit Care Res Pract 2012 2012 182324 23119151
5. Current trends in inflammatory and immunomodulatory mediators in sepsis. Aziz M, Jacob A, Yang WL, Matsuda A, Wang P, J Leukoc Biol 2013 93 329 342 10.1189/jlb.0912437 23136259
6. The role of innate immunity in septic acute kidney injuries. Goncalves GM, Zamboni DS, Camara NO, Shock 2010 34 22 26 10.1097/SHK.0b013e3181e7e69e 20523275
7. Novel therapeutic targets for sepsis: regulation of exaggerated inflammatory responses. Matsuda A, Jacob A, Wu R, Aziz M, Yang WL, Matsutani T, Suzuki H, Furukawa K, Uchida E, Wang P, J Nippon Med Sch 2012 79 4 18 10.1272/jnms.79.4 22398786
8. Clinical review: the liver in sepsis. Nesseler N, Launey Y, Aninat C, Morel F, Malledant Y, Seguin P, Crit Care 2012 16 235 10.1186/cc11381 23134597
9. Defining the cause of death in hospitalised patients with acute kidney injury. Selby NM, Kolhe NV, McIntyre CW, Monaghan J, Lawson N, Elliott D, Packington R, Fluck RJ, PLoS One 2012 7 48580 10.1371/journal.pone.0048580 23133643
10. Acute kidney injury, acute lung injury and septic shock: how does mortality compare? Vincent JL, Contrib Nephrol 2011 174 71 77 21921611
11. Timing the initiation of renal replacement therapy for acute kidney injury in Canadian intensive care units: a multicentre observational study. Clark E, Wald R, Levin A, Bouchard J, Adhikari NK, Hladunewich M, Richardson RM, James MT, Walsh MW, House AA, Moist L, Stollery DE, Burns KE, Friedrich JO, Barton J, Lafrance JP, Pannu N, Bagshaw SM, Canadian Acute Kidney Injury (CANAKI) Investigators, Can J Anaesth 2012 59 861 870 10.1007/s12630-012-9750-4 22752716
12. The severity of shock is associated with impaired rates of net alveolar fluid clearance in clinical acute lung injury. Zeyed YF, Bastarache JA, Matthay MA, Ware LB, Am J Physiol Lung Cell Mol Physiol 2012 303 550 L555 10.1152/ajplung.00190.2012 22821995
13. Expected and observed mortality in critically ill patients receiving initial antibiotic therapy. Janisch T, Wendt J, Hoffmann R, Ortlepp JR, Wien Klin Wochenschr 2012 124 775 781 10.1007/s00508-012-0276-0 23135688
14. Severe pneumococcal community-acquired pneumonia admitted to medical Tunisian ICU. Belkhouja K, Ben Romdhane K, Ghariani A, Hammami A, M'Hiri E, Slim-Saidi L, Ben Khelil J, Besbes M, J Infect Chemother 2012 18 324 331 10.1007/s10156-011-0337-8 22045164
15. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O, Scand J Immunol 2003 57 11 20 10.1046/j.1365-3083.2003.01176.x 12542793 (Pubitemid 38019084)
16. Autologous transplantation of adipose-derived mesenchymal stem cells markedly reduced acute ischemia-reperfusion lung injury in a rodent model. Sun CK, Yen CH, Lin YC, Tsai TH, Chang LT, Kao YH, Chua S, Fu M, Ko SF, Leu S, Yip HK, J Transl Med 2011 9 118 10.1186/1479-5876-9-118 21781312
17. Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology. Maumus M, Guerit D, Toupet K, Jorgensen C, Noel D, Stem Cell Res Ther 2011 2 14 10.1186/scrt55 21457518
18. Adipose-derived mesenchymal stem cell protects kidneys against ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. Chen YT, Sun CK, Lin YC, Chang LT, Chen YL, Tsai TH, Chung SY, Chua S, Kao YH, Yen CH, Shao PL, Chang KC, Leu S, Yip HK, J Transl Med 2011 9 51 10.1186/1479-5876-9-51 21545725
19. Mesenchymal stem cell therapy for attenuation of scar formation during wound healing. Jackson WM, Nesti LJ, Tuan RS, Stem Cell Res Ther 2012 3 20 10.1186/scrt111 22668751
20. Dynamics of branched tissue assembly. Manivannan S, Nelson CM, Stem Cell Res Ther 2012 3 42 10.1186/scrt133 23114096
21. The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. Thum T, Bauersachs J, Poole-Wilson PA, Volk HD, Anker SD, J Am Coll Cardiol 2005 46 1799 1802 10.1016/j.jacc.2005.07.053 16286162 (Pubitemid 41579799)
22. Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia-reperfusion injury. Yip HK, Chang YC, Wallace CG, Chang LT, Tsai TH, Chen YL, Chang HW, Leu S, Zhen YY, Tsai CY, Yeh KH, Sun CK, Yen CH, J Pineal Res 2013 54 207 221 10.1111/jpi.12020 23110436
23. Intravenous infusion of mesenchymal stem cells is associated with improved myocardial function during endotoxemia. Weil BR, Herrmann JL, Abarbanell AM, Manukyan MC, Poynter JA, Meldrum DR, Shock 2011 36 235 241 10.1097/SHK.0b013e318225f6ae 21654558
24. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee JW, Gupta N, Petrini M, Matthay MA, Am J Physiol Lung Cell Mol Physiol 2012 302 1003 L1013 10.1152/ajplung.00180.2011 22427530
25. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, Liles WC, Stewart DJ, Am J Respir Crit Care Med 2010 182 1047 1057 10.1164/rccm.201001-0010OC 20558630
26. Impact of apoptotic adipose-derived mesenchymal stem cells on attenuating organ damage and reducing mortality in rat sepsis syndrome induced by cecal puncture and ligation. Chang CL, Leu S, Sung HC, Zhen YY, Cho CL, Chen A, Tsai TH, Chung SY, Chai HT, Sun CK, Yen CH, Yip HK, J Transl Med 2012 10 244 10.1186/1479-5876-10-244 23217183
27. Immunodesign of experimental sepsis by cecal ligation and puncture. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA, Nat Protoc 2009 4 31 36 19131954
28. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Zhu W, Chen J, Cong X, Hu S, Chen X, Stem Cells 2006 24 416 425 10.1634/stemcells.2005-0121 16253984
29. Systemic human orbital fat-derived stem/stromal cell transplantation ameliorates acute inflammation in lipopolysaccharide-induced acute lung injury. Chien MH, Bien MY, Ku CC, Chang YC, Pao HY, Yang YL, Hsiao M, Chen CL, Ho JH, Crit Care Med 2012 40 1245 1253 10.1097/CCM.0b013e31823bc89a 22202710